Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced that Sam Samad, Executive ...

The Rising Wave of Esoteric Testing The Esoteric Testing Market represents a specialized segment of diagnostic laboratory services that focuses on rare and complex tests not routinely performed in ...

Quest Diagnostics has seen its Fair Value Estimate rise moderately from $191.56 to $197.25 per share, reflecting a more optimistic outlook among analysts. This upward revision is largely due to strong ...

The "Sepsis Diagnostics Market 2025-2029 - Global Market Forecasts by Assay, Cause, Product, Lab and Place, with Executive and Consultant Guides" has been added to ResearchAndMarkets.com's offering.

The Quest AD-Detect® blood-based test panels deliver confirmatory accuracy, potentially supporting reduced reliance on ...

Europe: Labcorp recently took a stake in SYNLAB, a big European lab company. This could be a way to test the waters and see ...

Labcorp plans to offer Roche’s recently FDA-cleared blood test to assess early signs of Alzheimer’s disease and other causes ...

A merger would significantly change the competitive scene. With Quest and Labcorp being major players, their combination ...

We came across a bullish thesis on Quest Diagnostics Incorporated on Quality Value Investing’s Substack by David J. Waldron.

Quest Diagnostics Incorporated shows post-pandemic growth with Q3 results, strategic expansion, and steady returns. Click for ...

Quest Diagnostics ( ($DGX) ) has released its Q3 earnings. Here is a breakdown of the information Quest Diagnostics presented to its investors.

Shares of Quest Diagnostics (NASDAQ: DGX) are falling Tuesday after the medical laboratories company shared mixed earnings ...